Products
Belantamab Biosimilar Antibody-Drug Conjugate (BCMA) for Research
Pre-Made Belantamab biosimilar, Whole mAb ADC, Anti-TNFRSF17 Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Belantamab mafodotin-blmf injection is used to treat multiple myeloma (a type of bone marrow cancer) in patients whose cancer has come back and who have received at least 4 previous treatments (eg, anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent) that did not work well.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-055-1mg | 1mg | 4635 |
| GMP-Bios-ab-055-10mg | 10mg | |
| GMP-Bios-ab-055-100mg | 100mg | |
| GMP-Bios-ab-055-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Belantamab biosimilar, Whole mAb ADC, Anti-TNFRSF17 Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A therapeutic antibody |
| INN Name | Belantamab |
| Target | TNFRSF17 |
| Format | Whole mAb ADC |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2017 |
| Year Recommended | 2018 |
| Companies | GlaxoSmithKline |
| Conditions Approved | Multiple myeloma |
| Conditions Active | na |
| Conditions Discontinued | na |
| Development Tech | na |
About target - TNFRSF17
1. Protein Tumor necrosis factor receptor superfamily member 17
2. Gene TNFRSF17
3. Organism Homo sapiens (Human)
Function
Receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. Promotes B-cell survival and plays a role in the regulation of humoral immunity. Activates NF-kappa-B and JNK.
